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Abstract   
Objective: To identify clinical and biomarker risk factors for preeclampsia in women 
with obesity and to explore interactions with gestational diabetes, a condition associated with 
preeclampsia.  
Study Design: In women with obesity (body mass index ≥30 kg/m2) from the UK 
Pregnancies Better Eating and Activity Trial (UPBEAT), we examined 8 clinical factors 
(socio-demographic characteristics, BMI, waist circumference and clinical variables) and 7 
biomarkers (HDL cholesterol, hemoglobin A1c, adiponectin, interleukin-6, high sensitivity 
C-reactive protein, and placental growth factor (PlGF)) in the early second trimester for 
association with later development of preeclampsia using logistic regression. Factors were 
selected based on prior association with preeclampsia. Interaction with gestational diabetes 
was assessed. 
Main outcome measure: Preeclampsia.  
Results: Prevalence of preeclampsia was 7.3% (59/824). Factors independently 
associated with preeclampsia were higher mean arterial blood pressure (Odds Ratio (OR) 
2.22; 95% Confidence Interval (CI) 1.58 to 3.12, per 10 mmHg) and lower PlGF (OR 1.39; 
95% CI 1.03 to 1.87, per each lower 1 log2). The association of PlGF with preeclampsia was 
present amongst obese women without gestational diabetes (OR 1.91; 95% CI 1.32 to 2.78), 
but not in those with GDM (OR 1.05; 95% CI 0.67 to 1.63), p=0.04 for interaction.  
Conclusion: The relationship between PlGF and preeclampsia differed in women 
with obesity according to gestational diabetes status, which may suggest different 
mechanistic pathways to preeclampsia. Whilst replication is required in other populations, 
this study suggests that performance of prediction models for preeclampsia should be 
confirmed in pre-specified subgroups. 
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Introduction  
Globally, preeclampsia is one of the principal causes of maternal and neonatal morbidity and 
mortality, with a prevalence of 3-5% in unselected populations.[1] The principal feature of 
preeclampsia is new onset hypertension with proteinuria after 20 weeks’ gestation. In the 
absence of curative treatment, management involves stabilization of the mother and fetus, 
followed by timely delivery. The cause of preeclampsia remains unclear but certain co-
morbidities predispose women to an increased risk, including gestational diabetes mellitus 
(GDM) and obesity, the focus of the present study.[2, 3] 
 
Obesity is increasing worldwide. By 2025, it is expected that one in every five women of 
reproductive age across the world will have obesity of whom at least 7-9% are likely to 
develop preeclampsia.[4] Some reports  suggest an associated increase in the prevalence of 
preeclampsia, however other risk factors, such as increasing maternal age and a reduction in 
smoking, may have contributed.[5] Insulin resistance and  a mild inflammatory state have 
been implicated in the pathophysiology of preeclampsia in women with obesity, which could 
also explain the association between GDM and preeclampsia.[3, 6, 7] However, in a recent 
study we found no evidence of a link between insulin resistance or inflammation biomarkers 
and preeclampsia in a group of nulliparous women with obesity.[8] As women with obesity 
who develop GDM have an exaggerated insulin resistance and inflammation biomarker 
profile[9], we hypothesized that the association of insulin resistance and inflammatory 
biomarkers with preeclampsia may be confined to women who develop GDM.  
 
The aim of this study was to identify clinical and biomarker risk factors for preeclampsia in 
women with obesity and to explore interaction with GDM status. This was undertaken as a 
secondary analysis of a large cohort of pregnant women with obesity, the UK Pregnancies 
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Better Eating and Activity Trial (UPBEAT), from whom a detailed clinical history had been 
obtained and blood samples taken in the early second trimester, prior to the development of 
preeclampsia.[10]  
 
Materials and Methods  
This study was a prospective cohort using data from UPBEAT, a randomized controlled trial 
of a complex behavioral intervention aimed at reducing GDM and large for gestational age 
infants.[10] UPBEAT recruited pregnant women with obesity (body mass index (BMI) ≥30 
kg/m
2
) with singleton pregnancies at 15
+0
 to 18
+6
 weeks’ gestation. Women were excluded if 
they had underlying disorders, including pre-pregnancy diagnosis of essential hypertension, 
diabetes, renal disease, systemic lupus erythematosus, antiphospholipid syndrome, sickle cell 
disease, thalassaemia, coeliac disease, thyroid disease, and current psychosis; or if they were 
currently being prescribed metformin. Detailed information was collected at trial entry (15
+0
 
to 18
+6
 weeks gestation) on maternal clinical characteristics, including socio-demographic 
information and anthropometric measures; non-fasting blood samples were also taken. 
Extensive information on maternal and infant outcomes was recorded.  Research ethics 
committee approval was obtained (UK Integrated Research Application System, reference 
09/H0802/5) and all women provided written consent. 
 
For the purpose of the present study, women with incomplete information on preeclampsia 
status, oral glucose tolerance test (OGTT) results, clinical and biomarker data were excluded. 
The UPBEAT intervention was not associated with a difference in the prevalence of 
preeclampsia or GDM[10], we therefore treated the study population as a cohort for the 
purpose of this analysis. 
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The primary outcome of the present study was preeclampsia which was defined according to 
the International Society for the study of Hypertension in Pregnancy (ISSHP) criteria: two 
measures of systolic (≥140 mmHg) or diastolic blood pressure (≥90 mmHg) taken at least 
four hours apart and the presence of proteinuria (spot urine protein/creatinine ≥30 mg/mmol 
[0.3 mg/mg] or ≥300 mg/day or at least 1 g/L [‘2 + ’] on dipstick testing).[11] For the 
purpose of this study, preeclampsia diagnosis was reviewed based on blood pressure and 
proteinuria values recorded by the research team. GDM, the pre-specified interaction 
analysis, was assessed by a universal screening 75 grams OGTT and diagnosis was based on 
the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria 
comprising one or more positive plasma glucose values: fasting ≥5.1 mmol/l, 1 hour ≥10.0 
mmol/l, 2 hour ≥8.5 mmol/l.[12, 13]  
 
Potential clinical risk factors included 8 variables selected on the basis of previously 
identified associations with preeclampsia and ability to translate to clinical practice. These 
were: age, nulliparity, BMI, waist circumference, known history of preeclampsia, first degree 
family history of hypertension and mean arterial blood pressure. Maternal sum of skinfold 
thicknesses (derived from the sum of mean triceps, biceps, subscapular, and suprailiac 
measurements made by trained research staff) was also explored due to its known association 
with BMI. Blood pressure was recorded using the pregnancy validated Microlife BP3BT0-A 
blood pressure monitor (Microlife, Widnau, Switzerland) and maternal skinfold thicknesses 
(triceps, biceps, suprailiac and subscapular) were measured in triplicate, using Harpenden 
skinfold Calipers (Holtain Ltd, Felin-y-Gigfran, Crosswell, UK).[14] Seven biomarkers were 
selected based on either a proposed role in preeclampsia pathogenesis in women with obesity, 
or a previously reported association with preeclampsia in weight heterogeneous women. 
These were: triglycerides, high-density lipoprotein (HDL), hemoglobin A1c (HbA1c), 
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adiponectin, interleukin-6 (IL-6), high sensitivity C Reactive Protein (hs-CRP), and placental 
growth factor (PlGF). Biomarker measurement methodology is described in the Appendix 
(Table A1).  
 
A complete case analysis was undertaken and we compared socio-demographic 
characteristics between the study population and women excluded from this analysis because 
of missing data. Assumptions for normality were checked for all predictors. Candidate 
biomarkers that showed positive skew were log transformed (triglycerides, HDL, 
adiponectin, IL-6, CRP, and PlGF). Transformation into log2 were performed so that odds 
ratios showed the effect associated with doubling the concentration. As low values of PlGF, 
are associated with preeclampsia, the scale was reversed, so that the odds ratio (OR) 
represented the increase in odds of preeclampsia associated with a reduction in PlGF. Clinical 
factors and biomarkers did not vary with gestational age at sampling, so additional correction 
for gestational age was not performed.  
 
Descriptive statistics were presented as means (SD), median (IQR) and frequency of 
observations (percentages), as appropriate. Comparisons of socio demographic characteristics 
and pregnancy outcomes between women with and without preeclampsia were performed 
using Chi-square tests, Wilcoxon rank-sum tests and t-tests as appropriate. Univariable 
logistic regression was used to investigate the association between clinical risk factors and 
biomarkers and the risk of development of preeclampsia later in pregnancy. Assessment of 
biomarkers was corrected for multiple testing using the False Discovery Rate (FDR).[15] 
Significant factors were identified if p<0.05 (FDR adjusted p-value for biomarkers) and were 
combined in a final multiple regression model for preeclampsia. To address the hypothesis 
that risk factors for preeclampsia may differ by GDM status, we explored the effect of pre-
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specified factors (PlGF, IL-6, CRP) and any significant risk factor in multivariable analysis 
on preeclampsia separately in women with and without GDM (stratified analysis). Likelihood 
ratio tests were then used to perform formal tests of interaction. Sensitivity analyses were 
performed using multiple imputation by chained equations to assess the potential for selection 
bias in complete case analysis. Outcomes (preeclampsia or GDM) were not imputed and 
women with missing outcomes were excluded from sensitivity analysis. Statistical analysis 
was performed using Stata software, version 14.2 (StataCorp LP, College Station, Texas). 
This study has been reported in line with STROBE recommendations.[16]  
 
Results  
Of the 1554 participants available for analysis, a total of 730 (47%) were excluded because of 
missing data for evaluation of preeclampsia diagnosis (n=47), OGTT results (n=251), clinical 
risk factors (n=43), and biomarker measurement (n=537) (Figure 1). Although no difference 
was observed in age, BMI and smoking status, participants excluded from this analysis were 
more likely of black ethnicity and multiparous (Appendix; Table A2). The study population 
comprised 824 women; the prevalence of preeclampsia was 7.2% (59/824), including 21 de 
novo cases of preeclampsia after review of clinical data. The majority of cases presented at 
term (n=49; 83.1%). The overall prevalence of preeclampsia was similar in all UPBEAT 
participants (6.3%). 
 
Socio-demographic characteristics of women with and without preeclampsia are shown in 
Table 1. The average age of all women was 30.6 (±5.4) years. Women with preeclampsia had 
higher BMI in early pregnancy and were more likely to be nulliparous. Age, education, 
ethnicity and smoking status were similar between groups. Women with preeclampsia were 
more likely to have labor induced (62.7% vs. 34.8%, p<0.01) and had a higher rate of preterm 
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delivery (17.0% vs. 3.9%, p<0.01), while their infants had lower median birth weight (3275 
g; IQR 2700-3600 g vs. 3490 g; IQR 3168-3795 g, p<0.01), lower Apgar scores (at 5 minutes 
<7, 6.8% vs. 1.4%, p<0.01), and were more likely to be admitted to neonatal intensive care 
unit (NICU) (18.6% vs. 7.2%, p<0.01). Women with preeclampsia also had a higher rate of 
stillbirth or neonatal mortality (5.1% vs. 0.5%, p<0.01). Amongst women with preeclampsia, 
the prevalence of any neonatal morbidity (combination of Apgar <7, NICU admission or 
fetal/neonatal mortality) was 34.8% (8/23) in women with GDM compared to 13.9% (5/36) 
in women without GDM (p=0.06).    
 
Clinical factors and biomarkers in women with and without preeclampsia are included in the 
Appendix (Table A3). Clinical factors associated with preeclampsia in univariable analyses 
were nulliparity (odds ratio (OR) 1.75; 95% Confidence Interval (CI) 1.02 to 2.99), BMI (OR 
1.07; 95% CI 1.03 to 1.12, per kg/m
2
), higher sum of skinfolds (OR 1.01; 95% CI 1.00 to 
1.02, per 1 mm), waist circumference (OR 1.03; 95% CI 1.01 to 1.05, per 1 cm) and mean 
arterial blood pressure (OR 2.43; 95% CI 1.06 to 1.13, per 10 mmHg) (Table 2). Correcting 
for multiple testing, reduced PlGF was the only biomarker associated with increased odds of 
developing preeclampsia (OR 1.46; 95% CI 1.10 to 1.94, per log2) in univariable analyses. In 
the multivariable regression, factors independently associated with preeclampsia were higher 
mean arterial blood pressure (OR 2.22; 95% CI 1.05 to 1.12, per 10 mmHg) and lower PlGF 
(OR 1.39; 95% CI 1.03 to 1.87, per log2) (Table 2).  
 
The prevalence of GDM was 29.6% (n=241/824). The rate of preeclampsia in women with 
GDM was 9.5% (n=23/241) and in women without GDM, 6.2% (n=36/583). Lower PlGF in 
the early second trimester increased the odds of preeclampsia only in women without GDM 
(OR 1.91; 95% CI 1.32 to 2.78, per log2); no association was evident in women with GDM 
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(OR 1.05; 95% CI 0.67 to 1.63, per log2) (Figure 2). This difference was evident in the 
interaction test (p=0.04) (Table 3). Higher IL-6 was associated with preeclampsia in women 
with GDM (OR 1.85; 95% CI 1.17 to 2.92, per log2) but not in women without GDM (OR 
1.25; 95% CI 0.87 to 1.79, per log2), although this was not significant in the interaction test 
(p=0.18).  Other clinical factors and biomarkers associated with preeclampsia in the full 
cohort did not differ by GDM status.  
 
The size of associations (odds ratios) and the confidence intervals were broadly similar in the 
complete case analysis and in the additional sensitivity analyses of imputed cases (Appendix; 
Table A4) and stratified analyses (Appendix; Table A5), except for nulliparity, which was 
independently associated with preeclampsia with the increased sample (sensitivity analysis). 
 
Discussion 
Whilst it is widely accepted that the etiology of preeclampsia is heterogeneous, evidence to 
suggest that risk factors for preeclampsia may differ according to specific high-risk 
subgroups is relatively new, and presents opportunities for personalized intervention 
strategies [8, 17] . To our knowledge, there has been no previous attempt to address risk 
factors for preeclampsia in women with obesity whose pregnancies are also complicated by 
GDM.  
 
Although we confirmed preeclampsia risk factors previously reported in a heterogeneous 
BMI population, notably raised mean arterial blood pressure and a reduced concentration of 
PlGF in early second trimester, we also report that PlGF, increasingly used in prediction or 
diagnosis of preeclampsia[18, 19], was not associated with preeclampsia in women with 
obesity who developed GDM. There was, however, a trend for an association between the 
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inflammatory mediator (IL-6) and preeclampsia in women who developed GDM.  These data 
support the hypothesis that different mechanisms may lead to preeclampsia in subgroups of 
women, and that in obese women who develop both preeclampsia and GDM, PlGF as a 
predictive/diagnostic test for preeclampsia may have limited use.  
 
While numerous epidemiological studies have demonstrated that obesity increases the risk of 
preeclampsia, the mechanisms have yet to be fully elucidated.[20, 21] Obesity is 
characterized by insulin resistance and an exaggerated state of inflammation and oxidative 
stress which have been implicated in pathways leading to preeclampsia.[6, 22] However, in a 
recent study of 834 women with obesity (BMI ≥30 kg/m2) and 3,106 lean nulliparous women 
(BMI 20-25 kg/m
2
) from the international Screening for Pregnancy Endpoints study 
(SCOPE) and in whom 53 relevant biomarkers were measured, we found no evidence of an 
association between markers of insulin resistance or inflammatory mediators measured at 
14
+0
 to 16
+0
 weeks’ gestation with later preeclampsia in either lean women or women with 
obesity.[8] Universal screening for GDM was not performed in SCOPE, which limited the 
assessment of an interaction of GDM in the association of risk factors at baseline and 
subsequent development of preeclampsia. In contrast, an OGTT was undertaken in all women 
included in the present study, enabling examination of interactions between GDM and risk 
factors for preeclampsia. 
 
The association of low PlGF with preeclampsia, which in the women in this study occurred 
predominantly at term, confirms our previous observations in women with obesity from the 
SCOPE cohort, [23] but is developed further here by the observation that it is restricted to 
women with obesity without GDM. Low values of PlGF, or the sFlt-1:PlGF ratio, are 
increasingly used in the prediction, diagnosis and ‘rule-out’ of preeclampsia.[18, 24-26] If 
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our observations  were to be replicated later in pregnancy, pre-eclampsia diagnostic or rule-
out tests using PlGF would require subgroup assessment. 
 
Raised IL-6 has been associated previously with later development of GDM and has been 
described in preeclampsia at the time of disease in unselected populations.[9, 27, 28] The  
observed trend between IL-6 (but not hs-CRP) and preeclampsia restricted to women with 
obesity and GDM warrants further study in larger cohorts.[29]  
 
Early second trimester mean arterial blood pressure was strongly associated with 
preeclampsia in this multi-ethnic heterogeneous population (Appendix; Table A2), 
confirming many previous reports recognizing that raised blood pressure in early pregnancy 
is a risk factor for preeclampsia in unselected populations.[25, 26] 
 
The strengths of our study include the prospective detailed data collection ensuring almost 
complete ascertainment of preeclampsia and GDM and the wide range of clinical factors, 
anthropometric measures and biomarkers available. Another strength is the precise definition 
of GDM using universal screening with a 75 grams OGTT in accordance with IADPSG and 
WHO recommendations. Measurement of sFlt-1 was not performed as the association with 
preeclampsia is confined to later pregnancy (after 20 weeks).[30, 31] Limitations include the 
47% (824/1,554) of participants excluded because of missing data with the potential for 
selection bias. However, a sensitivity analysis using multiple imputation which included 82% 
(1,276/1,554) of participants provided similar results. We did not perform universal 
assessment of uterine artery Doppler, a recognized risk factor for preeclampsia, but this 
reflects current clinical practice.[25, 26] Neither did we explore associations between PlGF 
later in pregnancy in relation to preeclampsia and GDM. The number of women with a 
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diagnosis of preeclampsia may have limited the power to detect some differences of smaller 
size. Given the  small numbers of cases of preeclampsia within each subgroup these findings, 
whilst novel,  require replication in larger studies. We also acknowledge that the absence of a 
lean group for comparison in this cohort is a limitation (i.e. no-obesity without GDM, no-
obesity with GDM).  
 
Conclusion 
The study of subgroups of women at high risk for preeclampsia has contributed to improved 
understanding of the heterogeneous etiology of this condition. Our results suggest that the 
relationship between PlGF and preeclampsia differs in women with obesity according to 
GDM status, which may indicate different pathways to disease. Studies seeking to translate 
the use of PlGF as predictive test for preeclampsia into clinical practice should consider sub-
group analysis according to obesity status.  
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Table 1. Socio-demographic characteristics and pregnancy outcomes according to 
preeclampsia status in women with obesity.    
Variable 
No preeclampsia 
Mean (SD) or n (%) 
n=765 
Preeclampsia 
Mean (SD) or n (%) 
n=59 
p value 
a 
Socio-demographic characteristics 
Age 30.7 (5.4) 30.0 (4.9) 0.36 
Body Mass Index
 b
 35.0 (32.8 - 38.3) 37.6 (33.1 - 42.0) 0.01 
Nulliparity 348 (45.5) 35 (59.3) 0.04 
Full time education, ≥12 years 686 (89.7) 53 (89.8) 0.97 
Ethnicity 
  
Asian 51 (6.7) 3 (5.1) 
 
Black 143 (18.7) 11 (18.6) 0.73 
Other 40 (5.2) 5 (8.5) 
 
White 531 (69.4) 40 (67.8) 
 
Smoking at baseline 52 (6.8) 3 (5.1) 0.73 
Pregnancy outcomes 
  
Induction of labor (n=823) 266 (34.8) 37 (62.7) <0.001 
GA at delivery 
b
, weeks (n=823) 39.9 (38.9 - 40.9) 38.7 (37.7 - 39.7) <0.001 
Preterm delivery (n=823) 29 (3.8) 10 (17.0) <0.001 
Birth weight 
b
, grams (n=823) 3490 (3170 - 3795) 3275 (2700 - 3600) <0.001 
Major PPH 
c
 (n=821) 115 (15.1) 12 (20.3) 0.28 
Mode of delivery (n=823) 
  
LSCS in labor 136 (17.8) 10  (17.0) 
 
Operative vaginal 91 (11.9) 8  (13.6) 0.29 
Prelabor LSCS 148 (19.4) 17 (28.8) 
 
Spontaneous vaginal 389 (50.9) 24 (40.7) 
 
Apgar <7 at 5 minutes (n=817) 11 (1.5) 4 (6.8) 0.003 
NICU admission (n=823) 55 (7.2) 11 (18.6) 0.002 
Stillborn or neonatal death 4 (0.5) 3 (5.1) <0.001 
Abbreviations: GA - gestational age, IQR – interquartile range, LSCS - lower segment 
caesarean section, NICU - neonatal intensive care unit, PPH - postpartum hemorrhage, SD – 
standard deviation, wks – weeks. 
a
 Comparisons performed using t-test or chi-squared test, as appropriate (unless otherwise 
stated); 
b
 Results presented as median (IQR); 
c
 Major PPH defined as estimated blood loss 
equal or above 1000 mls.
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Table 2. Clinical risk factors and biomarkers at 15
+0
-18
+6
 weeks’ gestation associated with preeclampsia in women with obesity (n=824).  
 
Univariable Analysis 
OR (95% CI) 
p value 
a
 p value 
b
 
Multivariable Analysis 
OR (95% CI) 
p value 
c
 
Age, years 0.98 (0.93 to 1.03) 0.36 0.36 
  
Nulliparous 1.75 (1.02 to 2.99) 0.04 0.04 1.50 (0.86 to 2.62) 0.15 
BMI  1.07 (1.03 to 1.12) 0.002 0.002 1.04 (0.96 to 1.13) 0.29 
Sum of skinfolds, mm 1.01 (1.00 to 1.02) 0.02 0.02 1.00 (0.99 to 1.02) 0.43 
Waist, cm 1.03 (1.01 to 1.05) 0.01 0.01 1.00 (0.97 to 1.04) 0.96 
Previous PE 2.53 (0.94 to 6.83) 0.07 0.07 
  
FH of hypertension 1.48 (0.87 to 2.51) 0.15 0.15 
  
MAP, per 10 mmHg 2.43 (1.75 to 3.37) <0.001 <0.001 2.22 (1.58 to 3.12) <0.001 
HDL, per log2 of mmol/l 0.48 (0.26 to 0.90) 0.02 0.05   
Triglycerides, per log2 of mmol/l 1.77 (1.02 to 3.08) 0.04 0.06   
HbA1c, mmol 1.07 (1.00 to 1.15) 0.04 0.07   
Adiponectin, per log2 of ug/ml 0.82 (0.62 to 1.09) 0.17 0.20   
IL-6, per log2 of pg/ml  1.46 (1.10 to 1.94) 0.008 0.06   
hs-CRP, per log2 of mg/L  1.15 (0.90 to 1.46) 0.27 0.27 
  
PlGF 
d
, per log2 of pg/ml  1.46 (1.10 to 1.94) 0.01 0.03 1.39 (1.03 to 1.87) 0.04 
Abbreviations: OR – odds ratio, CI – confidence interval, BMI – body mass index, PE – preeclampsia, FH – family history, MAP - mean 
arterial blood pressure, HDL - high-density lipoprotein, HbA1c - Hemoglobin A1c, IL-6 - interleukin-6, hs-CRP - high sensitivity C reactive 
protein, PlGF - inversed placental growth factor. 
a 
Crude p values (logistic regression); 
b 
False discovery rate (FDR) corrected p values are shown for biomarkers (logistic regression); 
c
 
multivariable logistic regression; 
d
 PlGF was inversed, the effect of a lower PlGF (per 1 log2 unit) is shown.
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Table 3. Risk factors for preeclampsia according to GDM status in women with obesity, and 
interaction test.   
 
No GDM 
OR (95% CI) 
n=583 
GDM 
OR (95% CI) 
n=241 
p value 
a
 
MAP, per 10 mmHg 2.48 (1.63 to 3.76) 2.23 (1.30 to 3.82) 0.76 
IL-6, per log2 of pg/ml 1.25 (0.87 to 1.79) 1.85 (1.17 to 2.92) 0.19 
hs-CRP, per log2 of mg/L
 
1.09 (0.81 to 1.48) 1.21 (0.80 to 1.83) 0.70 
PlGF 
b
, per log2 of pg/ml
 
1.91 (1.32 to 2.78) 1.05 (0.67 to 1.63) 0.04 
Abbreviations: OR – odds ratio, CI – confidence interval, MAP - mean arterial blood 
pressure, HDL - high-density lipoprotein, IL-6 - interleukin-6, hs-CRP - high sensitivity C 
reactive protein, PlGF – inversed placental growth factor. 
a
 Likelihood ratio tests for interaction; 
b
 PlGF was inversed; the effect of a lower PlGF (per 1 
log2 unit) is shown. 
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Figure 1: Study population  
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Figure 2. Observed probability of preeclampsia (95% confidence intervals) according to 
concentration of placental growth factor (PlGF) at 15
+0
-18
+6
 weeks’ gestation in women with 
obesity with and without gestational diabetes mellitus (GDM).  
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Gestational diabetes modifies the association between PlGF in early pregnancy and 
preeclampsia in women with obesity. 
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Table A1. Analytical methodologies for the biomarkers measured. 
Biomarker Sample Method Platform 
Triglycerides  Plasma Enzymatic, colorimetric Roche, Cobas c311 
HDL cholesterol  Plasma Homogenous Enzymatic, colorimetric Roche, Cobas c311 
HbA1c  Whole blood Turbidimetric inhibition immunoassay Roche, Cobas c311 
Adiponectin  Plasma Enzyme-linked immunosorbent assay R and D Systems 
Interleukin-6  Plasma Enzyme-linked immunosorbent assay R and D Systems 
C-reactive protein  Plasma Particle enhanced immunoturbidimetric Roche, Cobas c311 
PlGF Plasma Fluorescence Immunoassay Alere, Triage Meter Pro 
Abbreviations: HbA1c - haemoglobin A1c, HDL - high-density lipoprotein, PlGF –placental growth factor.
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Table A2. Socio-demographic characteristics of the complete case study population and 
UPBEAT participants excluded from this analysis.  
Variable 
Study participants 
n= 824 
Mean (SD) or n (%) 
Women excluded 
N=730 
Mean (SD) or n (%) 
p value 
Age 30.6 (5.4) 30.3 (5.7) 0.35 
Body Mass Index
 a
 35.2 (32.8- 38.5) 35.1 (32.8- 38.6) 0.77 
Nulliparity 383 (46.5) 291 (39.9) 0.009 
Full time education, ≥12 years 739 (89.7) 637 (87.3) 0.13 
Maternal ethnicity 
 
 
 
Asian 54 (6.6) 41 (5.6) 
 
Black 154 (18.7) 247 (33.8) <0.001 
Other 45 (5.5) 40 (5.5) 
 
White 571 (69.3) 402 (55.1) 
 
Smoking at 15
+0
-18
+6
 weeks' 
gestation 
55 (6.7) 53 (7.3) 0.65 
a
 Results presented as median (IQR) 
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Table A3. Descriptive statistics for clinical risk factors and biomarkers at 15
+0
-18
+6 
weeks 
according to preeclampsia status in women with obesity. 
 
No preeclampsia 
Mean (SD) or n (%) 
n=765 
Preeclampsia 
Mean (SD) or n (%) 
n=59 
Clinical risk factors 
 
Age, years 30.7 (5.4) 30.0 (4.9) 
Nulliparous 348 (45.5) 35 (59.3) 
Sum of skinfolds, mm 121 (26) 130 (28) 
Waist, cm 107.5 (10.2) 111.2 (12.7) 
Previous preeclampsia 27 (3.5) 5 (8.5) 
Family history of hypertension 328 (42.9) 31 (52.5) 
MAP, mmHg 87.7 (7.9) 93.7 (8.5) 
Biomarkers 
  
HDL, per log2 of mmol/l
 
0.60 (0.47) 0.46 (0.33) 
Triglycerides, per log2 of mmol/l
 
0.74 (0.46) 0.87 (0.46) 
HbA1c, mmol 29.37 (3.76) 30.43 (4.31) 
Adiponectin, per log2 of ug/ml
 
3.35 (0.92) 3.18 (0.81) 
IL-6, per log2 of pg/ml  1.57 (0.88) 1.89 (1.05) 
hs-CRP, per log2 of mg/L 
 
2.68 (1.14) 2.85 (1.04) 
PlGF 
a
, per log2 of pg/ml 
 
6.29 (0.94) 5.95 (1.02) 
Abbreviations: MAP - mean arterial blood pressure, HDL - high-density lipoprotein, HbA1c - 
haemoglobin A1c, IL-6 - interleukin-6, hs-CRP - high sensitivity C reactive protein, PlGF - 
placental growth factor. 
a
 PlGF was inversed; the effect of a lower PlGF (per 1 log2 unit) is shown. 
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Table A4. Sensitivity analysis using multiple imputation (n=1,276): Clinical risk factors and biomarkers at 15
+0
-18
+6
 weeks’ gestation 
associated with preeclampsia in women with obesity.  
 
Univariate Analysis 
OR (95% CI) 
p value
 a
 
Multivariate Analysis 
OR (95% CI) 
p value   
Age, years 0.98 (0.94 to 1.02) 0.34 
  
Body mass index  1.06 (1.02 to 1.10) 0.006 1.02 (0.95 to 1.09) 0.64 
Nulliparous 1.88 (1.16 to 3.03) 0.01 1.67 (1.02 to 2.74) 0.04 
Sum of skinfolds, mm 1.01 (1.01 to 1.02) 0.02 1.01 (1.00 to 1.01) 0.43 
Waist, cm 1.03 (1.01 to 1.05) 0.009 1.01 (0.98 to 1.04) 0.69 
Previous PE 3.64 (1.71 to 7.79) 0.001 
  
FH of hypertension 1.53 (0.95 to 2.45) 0.08 
  
MAP, per 10 mmHg 2.46 (1.85 to 3.27) <0.001 2.25 (1.67 to 3.04) <0.001 
HDL, per log2 of mmol/l
 
0.49 (0.27 to 0.87) 0.01 
  
Triglycerides, per log2 of mmol/l 2.09 (1.24 to 3.53) 0.006 
  
HbA1c, mmol 1.08 (1.01 to 1.15) 0.03 
  
Adiponectin, per log2 of ug/ml
 
0.81 (0.62 to 1.05) 0.11 
  
IL-6, per log2 of pg/ml 
 
1.46 (1.12 to 1.89) 0.005 
  
hs-CRP, per log2 of mg/L  1.17 (0.92 to 1.48) 0.20 
  
PlGF 
b
, per log2 of pg/ml 
 
1.41 (1.08 to 1.84) 0.01 1.33 (1.01 to 1.76) 0.05 
Abbreviations: OR – odds ratio, CI – confidence interval, PE – preeclampsia, FH – family history, MAP - mean arterial blood pressure, HDL - 
high-density lipoprotein, HbA1c - Haemoglobin A1c, IL-6 - interleukin-6, hs-CRP - high sensitivity C reactive protein, PlGF - inversed 
placental growth factor.   
a 
Crude results presented, correction for False Discovery Rate was not performed; 
b
 PlGF was inversed, the effect of a lower PlGF (per 1 log2 
unit) is shown. 
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Table A5. Sensitivity analysis using multiple imputation (n=1,276): Risk factors for 
preeclampsia according to GDM status in women with obesity. 
 
No GDM 
OR (95% CI) 
n=947 
GDM 
OR (95% CI) 
n=329 
MAP, per 10 mmHg 2.52 (1.75 to 3.63) 2.15 (1.33 to 3.48) 
IL-6, per log2 of pg/ml
 
1.29 (0.93 to 1.80) 1.80 (1.16 to 2.78) 
hs-CRP, per log2 of mg/L
 
1.11 (0.82 to 1.49) 1.23 (0.84 to 1.80) 
PlGF 
a
, per log2 of pg/ml
 
1.72 (1.22 to 2.43) 1.12 (0.73 to 1.70) 
Abbreviations: OR – odds ratio, CI – confidence interval, MAP - mean arterial blood 
pressure, HDL - high-density lipoprotein, IL-6 - interleukin-6, hs-CRP - high sensitivity C 
reactive protein, PlGF – inversed placental growth factor. 
a
 PlGF was inversed; the effect of a lower PlGF (per 1 log2 unit) is shown. 
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